Core Viewpoint - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis treatment [1][7]. Company Summary - On September 15, 2025, aTyr announced that its EFZO-FIT trial did not achieve statistical significance in steroid reduction after a year of tapering, leading to a significant market reaction [7]. - The company had previously assured investors that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [6]. Investigation Summary - Following the market reaction, Hagens Berman, a national shareholders rights firm, initiated an investigation into whether aTyr misled investors regarding its Phase 2 data and Phase 3 trial design [2][5]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 data and the design of the EFZO-FIT trial [5]. Market Reaction - The announcement of the topline results led to a flood of analyst downgrades and a catastrophic drop in aTyr's share price, reflecting investor disappointment and loss of confidence [7].

Core Insights - Class actions have been initiated for stockholders of Altimmune, Inc. and SelectQuote, Inc. with deadlines for lead plaintiff petitions approaching [1] Altimmune, Inc. (NASDAQ:ALT) - The class period for Altimmune is from August 10, 2023, to June 25, 2025, with a lead plaintiff deadline of October 6, 2025 [2] - On June 26, 2025, Altimmune announced disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, failing to achieve statistical significance in the primary endpoint of fibrosis reduction due to a higher-than-expected placebo response [2] - Following the announcement, Altimmune's stock price plummeted from $7.71 to $3.61 per share, marking a decline of 53.2% in one day [3] SelectQuote, Inc. (NYSE:SLQT) - The class period for SelectQuote is from September 9, 2020, to May 1, 2025, with a lead plaintiff deadline of October 10, 2025 [3] - On May 1, 2025, the U.S. Department of Justice filed a complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to 2021 [3] - The complaint claims SelectQuote misled Medicare beneficiaries by stating it offered unbiased coverage comparisons while actually directing them to plans that paid SelectQuote the most, resulting in a stock price drop of $0.61, or 19.2%, to close at $2.56 per share on the same day [3][4]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [2][3]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death linked to the trial, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [3]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [3]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements or omissions by companies [4].